Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development. Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer. Immutep has collaboration with Merck & Co., Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia. more
Time Frame | IMMP | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.59% | -3.72% | -0.05% |
1-Month Return | 5.58% | -1.85% | 2.75% |
3-Month Return | -9.96% | -11.4% | 7.4% |
6-Month Return | -22.68% | -4.41% | 10.47% |
1-Year Return | -11.49% | 4.13% | 27.57% |
3-Year Return | -36.97% | 0.3% | 29.56% |
5-Year Return | 23.81% | 36.62% | 89.3% |
10-Year Return | -28.28% | 106.81% | 206.09% |
Jun '20 | Jun '21 | Jun '22 | Jun '23 | Jun '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 7.49M | 3.97M | 170.37K | 3.51M | 3.84M | [{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":53,"profit":true},{"date":"2022-06-30","value":2.28,"profit":true},{"date":"2023-06-30","value":46.83,"profit":true},{"date":"2024-06-30","value":51.32,"profit":true}] |
Cost of Revenue | 22.47M | 2.07M | 2.06M | 2.06M | 41.55M | [{"date":"2020-06-30","value":54.09,"profit":true},{"date":"2021-06-30","value":4.98,"profit":true},{"date":"2022-06-30","value":4.97,"profit":true},{"date":"2023-06-30","value":4.96,"profit":true},{"date":"2024-06-30","value":100,"profit":true}] |
Gross Profit | (14.99M) | 1.90M | (1.89M) | 1.44M | (37.70M) | [{"date":"2020-06-30","value":-789.57,"profit":false},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":-99.74,"profit":false},{"date":"2023-06-30","value":76.07,"profit":true},{"date":"2024-06-30","value":-1986.54,"profit":false}] |
Gross Margin | (200.18%) | 47.83% | (1111.18%) | 41.19% | (981.42%) | [{"date":"2020-06-30","value":-418.51,"profit":false},{"date":"2021-06-30","value":100,"profit":true},{"date":"2022-06-30","value":-2323.11,"profit":false},{"date":"2023-06-30","value":86.11,"profit":true},{"date":"2024-06-30","value":-2051.82,"profit":false}] |
Operating Expenses | 22.56M | 19.66M | 34.01M | 42.88M | 50.40M | [{"date":"2020-06-30","value":44.76,"profit":true},{"date":"2021-06-30","value":39,"profit":true},{"date":"2022-06-30","value":67.48,"profit":true},{"date":"2023-06-30","value":85.07,"profit":true},{"date":"2024-06-30","value":100,"profit":true}] |
Operating Income | (16.02M) | (19.56M) | (33.94M) | (44.94M) | (88.10M) | [{"date":"2020-06-30","value":-1601888200,"profit":false},{"date":"2021-06-30","value":-1956057700,"profit":false},{"date":"2022-06-30","value":-3393755400,"profit":false},{"date":"2023-06-30","value":-4493703000,"profit":false},{"date":"2024-06-30","value":-8810418600,"profit":false}] |
Total Non-Operating Income/Expense | 2.74M | 1.87M | 1.82M | 5.96M | - | [{"date":"2020-06-30","value":45.97,"profit":true},{"date":"2021-06-30","value":31.37,"profit":true},{"date":"2022-06-30","value":30.52,"profit":true},{"date":"2023-06-30","value":100,"profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Pre-Tax Income | (13.47M) | (29.90M) | (32.21M) | (39.90M) | (42.72M) | [{"date":"2020-06-30","value":-1346819500,"profit":false},{"date":"2021-06-30","value":-2990259100,"profit":false},{"date":"2022-06-30","value":-3221079200,"profit":false},{"date":"2023-06-30","value":-3989634800,"profit":false},{"date":"2024-06-30","value":-4271662500,"profit":false}] |
Income Taxes | 37.00 | 33.00 | 34.00 | 2.00 | 2.00 | [{"date":"2020-06-30","value":100,"profit":true},{"date":"2021-06-30","value":89.19,"profit":true},{"date":"2022-06-30","value":91.89,"profit":true},{"date":"2023-06-30","value":5.41,"profit":true},{"date":"2024-06-30","value":5.41,"profit":true}] |
Income After Taxes | (13.47M) | (29.90M) | (32.21M) | (39.90M) | - | [{"date":"2020-06-30","value":-1346823200,"profit":false},{"date":"2021-06-30","value":-2990262400,"profit":false},{"date":"2022-06-30","value":-3221082600,"profit":false},{"date":"2023-06-30","value":-3989635000,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
Income From Continuous Operations | (13.47M) | (29.90M) | (46.82M) | (39.90M) | - | [{"date":"2020-06-30","value":-1346823200,"profit":false},{"date":"2021-06-30","value":-2990262400,"profit":false},{"date":"2022-06-30","value":-4682423354,"profit":false},{"date":"2023-06-30","value":-3989634800,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-06-30","value":"-","profit":true},{"date":"2021-06-30","value":"-","profit":true},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":"-","profit":true},{"date":"2024-06-30","value":"-","profit":true}] |
Net Income | (13.47M) | (29.90M) | (32.21M) | (39.90M) | (42.72M) | [{"date":"2020-06-30","value":-1346823200,"profit":false},{"date":"2021-06-30","value":-2990262400,"profit":false},{"date":"2022-06-30","value":-3221082600,"profit":false},{"date":"2023-06-30","value":-3989634800,"profit":false},{"date":"2024-06-30","value":-4271662500,"profit":false}] |
EPS (Diluted) | (0.03) | (0.40) | - | (0.30) | - | [{"date":"2020-06-30","value":-3.05,"profit":false},{"date":"2021-06-30","value":-40.04,"profit":false},{"date":"2022-06-30","value":"-","profit":true},{"date":"2023-06-30","value":-30.26,"profit":false},{"date":"2024-06-30","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
IMMP | |
---|---|
Cash Ratio | 17.34 |
Current Ratio | 18.25 |
Quick Ratio | 18.07 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IMMP | |
---|---|
ROA (LTM) | -16.67% |
ROE (LTM) | -26.21% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IMMP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.06 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.94 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IMMP | |
---|---|
Trailing PE | NM |
Forward PE | 7.65 |
P/S (TTM) | 88.04 |
P/B | 2.63 |
Price/FCF | NM |
EV/R | 803.42 |
EV/Ebitda | NM |
Immutep Ltd ADR (IMMP) share price today is $2.08
Yes, Indians can buy shares of Immutep Ltd ADR (IMMP) on Vested. To buy Immutep Ltd ADR from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IMMP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Immutep Ltd ADR (IMMP) via the Vested app. You can start investing in Immutep Ltd ADR (IMMP) with a minimum investment of $1.
You can invest in shares of Immutep Ltd ADR (IMMP) via Vested in three simple steps:
The 52-week high price of Immutep Ltd ADR (IMMP) is $3.33. The 52-week low price of Immutep Ltd ADR (IMMP) is $1.66.
The price-to-earnings (P/E) ratio of Immutep Ltd ADR (IMMP) is
The price-to-book (P/B) ratio of Immutep Ltd ADR (IMMP) is 2.63
The dividend yield of Immutep Ltd ADR (IMMP) is 0.00%
The market capitalization of Immutep Ltd ADR (IMMP) is $338.25M
The stock symbol (or ticker) of Immutep Ltd ADR is IMMP